Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...